Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
COCP similar filings
- 28 Mar 24 Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
- 19 Mar 24 Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
- 1 Mar 24 Termination of a Material Definitive Agreement
- 8 Jan 24 Regulation FD Disclosure
- 4 Jan 24 Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
- 21 Dec 23 Termination of a Material Definitive Agreement
- 6 Dec 23 Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
Filing view
External links
Exhibit 99.1